AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12073414 — intervention group
Group type: COMPARATOR
Intervention: Control group (913 patients)
Number of subjects: 2626
Study 9458201 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients
Number of subjects: 106
Study 7629414 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine (BL)
Number of subjects: 7
Study 7629414 — intervention group
Group type: COMPARATOR
Intervention: Unbuffered lidocaine (L)
Number of subjects: 7
Study 2611076 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine 0.3 mg kg‐1
Number of subjects: 80
Study 2611076 — intervention group
Group type: COMPARATOR
Intervention: morphine 0.15 mg kg‐1
Number of subjects: 80
Study 1195025 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial group (no knowledge of medical evaluation results)
Number of subjects: 4936
Study 1195025 — intervention group
Group type: COMPARATOR
Intervention: Control group (results of medical evaluation fully disclosed)
Number of subjects: 4936
Study 1195025 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial group (medical evaluation category A - normal risk)
Number of subjects: 4936
Study 1195025 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial group (no preemployment medical evaluation)
Number of subjects: 4936
Study 1195025 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemployment health evaluation
Number of subjects: 4936
Study 30887731 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-L·kg·min-1
Number of subjects: 168
Study 30887731 — intervention group
Group type: COMPARATOR
Intervention: 2-L·kg·min-1
Number of subjects: 168
Study 28034609 — intervention group
Group type: EXPERIMENTAL
Intervention: Respecting the Circle of Life (RCL) intervention
Number of subjects: 267
Study 25524798 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 165
Study 25524798 — intervention group
Group type: COMPARATOR
Intervention: Letrozole alone
Number of subjects: 165
Study 25524798 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole (Cohort 1)
Number of subjects: 165
Study 25524798 — intervention group
Group type: COMPARATOR
Intervention: Letrozole alone (Cohort 1)
Number of subjects: 165
Study 25524798 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole (Cohort 2)
Number of subjects: 165
Study 25524798 — intervention group
Group type: COMPARATOR
Intervention: Letrozole alone (Cohort 2)
Number of subjects: 165
Study 23645608 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial health warnings (PHWs) on cigarette packages
Number of subjects: 500
Study 21609504 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment with feedback during individual treatment (using Readiness to Change Questionnaire and Personal Resources Diagnostic System)
Number of subjects: 280
Study 21609504 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment without within treatment assessment with feedback
Number of subjects: 280
Study 21609504 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment with feedback during individual treatment
Number of subjects: 280
Study 19104843 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Education Program (PEP)
Number of subjects: 120
Study 19104843 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 120
Study 17764789 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous immunisation (TCI) with live-attenuated measles vaccine ROUVAX
Number of subjects: 0
Study 17764789 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous route
Number of subjects: 0
Study 15075414 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported medications
Number of subjects: 294
Study 15075414 — intervention group
Group type: COMPARATOR
Intervention: Pharmacy records
Number of subjects: 294
Study 15075414 — intervention group
Group type: EXPERIMENTAL
Intervention: Health status
Number of subjects: 294
Study 11251037 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular adsorbent recirculating system (MARS) treatment for 6-8 hours
Number of subjects: 400
Study 11251037 — intervention group
Group type: EXPERIMENTAL
Intervention: MARS treatment
Number of subjects: 400
Study 9291514 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency physicians prescribing narcotics (codeine or oxycodone compounds)
Number of subjects: 165
Study 9291514 — intervention group
Group type: COMPARATOR
Intervention: Family practice physicians prescribing narcotics
Number of subjects: 165
Study 9291514 — intervention group
Group type: COMPARATOR
Intervention: Pediatricians prescribing narcotics
Number of subjects: 165
Study 9291514 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall physician willingness to prescribe stronger medications than acetaminophen or NSAIDs
Number of subjects: 165
Study 9291514 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of narcotic prescriptions for 2-year-old vs 22-year-old patients
Number of subjects: 165
Study 9291514 — intervention group
Group type: COMPARATOR
Intervention: Comparison of narcotic prescriptions between pediatricians and family practice physicians
Number of subjects: 165
Study 8184497 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dynamic back extension and abdominal exercises without low back pain being the limiting factor
Number of subjects: 96
Study 8184497 — intervention group
Group type: COMPARATOR
Intervention: Traditional mild, general mobility-improving exercises within pain limits
Number of subjects: 96
Study 8184497 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (not specified intervention)
Number of subjects: 96
Study 2453700 — intervention group
Group type: EXPERIMENTAL
Intervention: Allapinin (0.39 mg/kg)
Number of subjects: 42
Study 2453700 — intervention group
Group type: EXPERIMENTAL
Intervention: Allapinin (doses > 0.32 mg/kg)
Number of subjects: 42
Study 2453700 — intervention group
Group type: EXPERIMENTAL
Intervention: Allapinin (doses > 0.42 mg/kg)
Number of subjects: 42
Study 2453700 — intervention group
Group type: EXPERIMENTAL
Intervention: Allapinin
Number of subjects: 42
Study 29599478 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR) supplementation
Number of subjects: 0
Study 29599478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27631142 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20-60 mg/d) for 8-14 weeks
Number of subjects: 3577
Study 24205974 — intervention group
Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg once daily
Number of subjects: 194
Study 24205974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 22392835 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen inhalation at a rate of 15 L/min for 3 min
Number of subjects: 179
Study 22392835 — intervention group
Group type: COMPARATOR
Intervention: Control group (noncirrhotic patients)
Number of subjects: 179
Study 22392835 — intervention group
Group type: EXPERIMENTAL
Intervention: Child‐Pugh class A
Number of subjects: 179
Study 22392835 — intervention group
Group type: EXPERIMENTAL
Intervention: Child‐Pugh class B/C
Number of subjects: 179
Study 19939723 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal stabilisation exercises
Number of subjects: 9
Study 18290881 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-slice multidetector computed tomography (MDCT)
Number of subjects: 30
Study 15859361 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (CE) 200 mg administered in refracted doses
Number of subjects: 9
Study 15859361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 11836044 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/day
Number of subjects: 72
Study 11836044 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine estrogens 0.6 mg plus sequential medrogestone 5 mg (CEE/M)
Number of subjects: 72
Study 10881067 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal splenorenal shunt (PSS)
Number of subjects: 73
Study 10881067 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt (DSS)
Number of subjects: 73
Study 10881067 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophagogastric devascularization with splenectomy (EGDS)
Number of subjects: 73
Study 10881067 — intervention group
Group type: COMPARATOR
Intervention: Differential grading analysis between PSS and EGDS
Number of subjects: 73
Study 10881067 — intervention group
Group type: COMPARATOR
Intervention: Differential grading analysis between proximal and distal splenorenal shunts
Number of subjects: 73
Study 7538237 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide (50 mg once daily) plus LHRH analogue therapy
Number of subjects: 813
Study 7538237 — intervention group
Group type: COMPARATOR
Intervention: Flutamide (250 mg three times daily) plus LHRH analogue therapy
Number of subjects: 813
Study 7538237 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide plus LHRH analogue therapy
Number of subjects: 813
Study 7538237 — intervention group
Group type: COMPARATOR
Intervention: Flutamide plus LHRH analogue therapy
Number of subjects: 813
Study 1835650 — intervention group
Group type: EXPERIMENTAL
Intervention: Norplant (levonorgestrel)
Number of subjects: 120
Study 1835650 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable norethisterone enanthate
Number of subjects: 120
Study 1835650 — intervention group
Group type: COMPARATOR
Intervention: IUD
Number of subjects: 120
Study 1835650 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ring releasing 10 mg of natural progesterone per 24 h
Number of subjects: 120
Study 1835650 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural progesterone as a contraceptive
Number of subjects: 120
Study 6217949 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (0.04 mg per dose, 3 times daily)
Number of subjects: 43
Study 6217949 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (0.2 mg per dose, 3 times daily)
Number of subjects: 43
Study 31063869 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin in combination with Alcohol Behavioral Couples Therapy (ABCT)
Number of subjects: 0
Study 31063869 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with Alcohol Behavioral Couples Therapy (ABCT)
Number of subjects: 0
Study 29194267 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (Group B)
Number of subjects: 22
Study 29194267 — intervention group
Group type: COMPARATOR
Intervention: Control (Group A)
Number of subjects: 22
Study 26520160 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention arm
Number of subjects: 107
Study 26520160 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 107
Study 26520160 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recruitment strategy
Number of subjects: 107
Study 26520160 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum recruitment
Number of subjects: 107
Study 24747932 — intervention group
Group type: EXPERIMENTAL
Intervention: Care management intervention for PTSD
Number of subjects: 404
Study 24747932 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 404
Study 21355042 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 32
Study 21355042 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 32
Study 19095663 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 40
Study 19095663 — intervention group
Group type: COMPARATOR
Intervention: Orlistat
Number of subjects: 40
Study 17985808 — intervention group
Group type: EXPERIMENTAL
Intervention: Shamanic treatment during 5 treatment visits
Number of subjects: 23
Study 16288823 — intervention group
Group type: EXPERIMENTAL
Intervention: Reach-to-grasp tasks of different levels of complexity
Number of subjects: 65
Study 16288823 — intervention group
Group type: EXPERIMENTAL
Intervention: Strongly lateralized children
Number of subjects: 65
Study 16288823 — intervention group
Group type: EXPERIMENTAL
Intervention: Less lateralized children
Number of subjects: 65
Study 12700990 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with local anesthetics
Number of subjects: 0
Study 12700990 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 0
Study 12700990 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative food intake
Number of subjects: 0
Study 12700990 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic laxatives and prokinetic drugs (e.g., erythromycin, acetylcholinesterase inhibitors)
Number of subjects: 0
Study 12700990 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of epidural anesthesia, sparse use of i.v. opioids, early food intake, and laxatives/prokinetics
Number of subjects: 0
Study 11011459 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctors made aware of a prize
Number of subjects: 700
Study 11011459 — intervention group
Group type: COMPARATOR
Intervention: Telephone call introduction
Number of subjects: 700
Study 11011459 — intervention group
Group type: COMPARATOR
Intervention: Postcard introduction
Number of subjects: 700
Study 11011459 — intervention group
Group type: EXPERIMENTAL
Intervention: Female doctors
Number of subjects: 700
Study 11011459 — intervention group
Group type: COMPARATOR
Intervention: Rural doctors
Number of subjects: 700
Study 11011459 — intervention group
Group type: COMPARATOR
Intervention: Practice Assessment activity
Number of subjects: 700
Study 8666632 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy extracorporeal shock-wave therapy (3000 impulses of 0.08 mJ/mm2)
Number of subjects: 100
Study 8666632 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 impulses)
Number of subjects: 100
Study 1632402 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril (n = 114)
Number of subjects: 172
Study 1632402 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 58)
Number of subjects: 172
Study 6660926 — intervention group
Group type: EXPERIMENTAL
Intervention: Org OD 14
Number of subjects: 35
Study 6660926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 30692052 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymectomy plus prednisone
Number of subjects: 68
Study 30692052 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 68
Study 29847684 — intervention group
Group type: EXPERIMENTAL
Intervention: Written patient admission and discharge evaluation method
Number of subjects: 0
Study 29847684 — intervention group
Group type: COMPARATOR
Intervention: High-fidelity simulation manikin evaluation method
Number of subjects: 0
Study 27565831 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated exposure to recommended amounts of vegetables
Number of subjects: 0
Study 27565831 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding vegetables to the diet
Number of subjects: 0
Study 27565831 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitution of vegetables in the diet
Number of subjects: 0
Study 27565831 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of bone turnover
Number of subjects: 0
Study 27565831 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported secondary outcomes measured by questionnaire
Number of subjects: 0
Study 24599578 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of aerobic exercise (STAN; 25 to 30 minutes, thrice weekly)
Number of subjects: 301
Study 24599578 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of aerobic exercise (HIGH; 50 to 60 minutes, thrice weekly)
Number of subjects: 301
Study 24599578 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dose of aerobic and resistance exercise (COMB; 50 to 60 minutes, thrice weekly)
Number of subjects: 301
Study 24599578 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of aerobic exercise (STAN)
Number of subjects: 301
Study 24599578 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of aerobic exercise (HIGH) and Combined exercise (COMB)
Number of subjects: 301
Study 23285019 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein (HP) diet
Number of subjects: 20
Study 23285019 — intervention group
Group type: COMPARATOR
Intervention: Low Protein (LP) diet
Number of subjects: 20
Study 23285019 — intervention group
Group type: COMPARATOR
Intervention: Normal Protein (NP) diet
Number of subjects: 20
Study 23285019 — intervention group
Group type: COMPARATOR
Intervention: Fecal water genotoxicity
Number of subjects: 20
Study 23285019 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolite profiles
Number of subjects: 20
Study 20233640 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress day (cortisol measured pre- and post-stress)
Number of subjects: 0
Study 20233640 — intervention group
Group type: COMPARATOR
Intervention: Rest day control (cortisol measured at the same time of day and for the same duration)
Number of subjects: 0
Study 17949394 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-containing cigarettes
Number of subjects: 49
Study 17949394 — intervention group
Group type: COMPARATOR
Intervention: Nicotine-free cigarettes
Number of subjects: 49
Study 17949394 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of alcoholism (FH+)
Number of subjects: 49
Study 16230587 — intervention group
Group type: EXPERIMENTAL
Intervention: Meniett device
Number of subjects: 61
Study 16230587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 12390642 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin treatment
Number of subjects: 9
Study 12390642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9926949 — intervention group
Group type: EXPERIMENTAL
Intervention: Vastus muscle-splitting approach
Number of subjects: 100
Study 9926949 — intervention group
Group type: COMPARATOR
Intervention: Median parapatellar approach
Number of subjects: 100
Study 7753456 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMW heparin)
Number of subjects: 0
Study 7753456 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UF heparin)
Number of subjects: 0
Study 7753456 — intervention group
Group type: EXPERIMENTAL
Intervention: Heptest assay from plasma samples
Number of subjects: 0
Study 2196971 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous indomethacin
Number of subjects: 116
Study 2196971 — intervention group
Group type: COMPARATOR
Intervention: Rectal indomethacin
Number of subjects: 116
Study 6782609 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 30
Study 6782609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 27862055 — intervention group
Group type: EXPERIMENTAL
Intervention: SCORRE intervention (motivational video, LS7 risk assessment, 6-week behavioral diary)
Number of subjects: 30
Study 27862055 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 25920709 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent radiotherapy (60 Gy over 6 weeks) and temozolomide (75 mg/m(2)), followed by six adjuvant 28‐day cycles of either dose‐dense (150 mg/m(2), days 1‐7, 15‐21) or metronomic (50 mg/m(2), days 1‐28) temozolomide, and maintenance RA (100 mg/m(2), days 1‐21/28) until disease progression.
Number of subjects: 31
Study 25146067 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet cupping combined with dietary advice
Number of subjects: 126
Study 25146067 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice alone (Control)
Number of subjects: 126
Study 22030896 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761 (120 mg two times a day)
Number of subjects: 41
Study 22030896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 22030896 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761
Number of subjects: 41
Study 20232789 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17464093 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine therapy
Number of subjects: 31
Study 17464093 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy young women)
Number of subjects: 31
Study 15107657 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0
Study 15107657 — intervention group
Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 0
Study 12434933 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity millimeter waves
Number of subjects: 0
Study 9743274 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraliminal target stimuli
Number of subjects: 0
Study 9743274 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal target stimuli
Number of subjects: 0
Study 9743274 — intervention group
Group type: COMPARATOR
Intervention: Frequent stimuli
Number of subjects: 0
Study 8066195 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated megavoltage imaging system for patient repositioning during radiotherapy
Number of subjects: 0
Study 3289433 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone followed by recombinant interferon alpha-2b
Number of subjects: 39
Study 3289433 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 39
Study 31084985 — intervention group
Group type: EXPERIMENTAL
Intervention: RIPCmultiple (daily RIPC for 6 days plus RIPC during 40 min before LPS), n=10
Number of subjects: 30
Study 31084985 — intervention group
Group type: EXPERIMENTAL
Intervention: RIPCsingle (RIPC only during 40 min before LPS), n=10
Number of subjects: 30
Study 31084985 — intervention group
Group type: COMPARATOR
Intervention: Control (no RIPC before LPS), n=10
Number of subjects: 30
Study 28284500 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BNP
Number of subjects: 476
Study 28284500 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BigET-1
Number of subjects: 476
Study 28284500 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative changes in BNP after 1 month
Number of subjects: 476
Study 28284500 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative changes in BigET-1 after 1 month
Number of subjects: 476
Study 28284500 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined baseline and changes in BigET-1 with BNP
Number of subjects: 476
Study 25788234 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Number of subjects: 699
Study 25788234 — intervention group
Group type: COMPARATOR
Intervention: Surgical Aortic Valve Replacement (SAVR)
Number of subjects: 699